Biosimilar Labeling: FDA Says Leave Comparability Data Out
Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.
Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.